Employees: 350
Size Tauns Laboratories (197A.T) is a Japan Health Care company (Medical Specialties) with a market value of $327M, the 1303rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥487 on 18 Nov 2026.
Performance Over six months the shares fell 3.2%, against -20.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 7.2% over the last twelve months (peer median +2.2%); the operating margin is 29.3% (peer median 7.9%).
Valuation It trades at 16.7× forward earnings against a peer median of 17.8× (6th cheapest of 13).
Capital Return on invested capital runs 4.1 points above its cost of capital (5.2% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥15.6B | ¥14.4B | ¥18.6B | ¥18.4B | ¥15.7B |
| Revenue growth | — | -23% | +1% | +18% | — |
| Gross profit | ¥9.46B | ¥8.29B | ¥12.3B | ¥12.1B | ¥8.79B |
| EBITDA | ¥5.92B | ¥5.33B | ¥8.98B | ¥8.71B | ¥5.61B |
| Net income | ¥5.71B | ¥5.50B | ¥6.32B | ¥5.77B | ¥3.03B |
| Free cash flow | n/a | -¥6.61B | ¥2.14B | ¥6.18B | -¥4.25B |
| Capital expenditure | n/a | ¥4.02B | ¥5.12B | ¥3.96B | ¥1.17B |
| Total debt | ¥19.9B | ¥21.3B | ¥14.4B | ¥9.54B | ¥6.47B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 197A.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.8% | -10.9% | 8th highest of 21 |
| 6-month return | -3.2% | -20.4% | 7th highest of 21 |
| Distance from 52-week high | -15.6% | -48.0% | 3rd highest of 21 |
| Revenue growth (TTM) | +7.2% | +2.2% | 10th highest of 21 |
| Operating margin | 29.3% | 7.9% | 4th highest of 21 |
| Forward P/E | 16.7× | 17.8× | 6th cheapest of 13 |
| ROIC minus cost of capital | +4.1 pp | +1.9 pp | 10th highest of 19 |
| EV / EBITDA | 11.5× | 7.8× | 4th most expensive of 10 |
| Net debt / EBITDA | 2.7× | 1.3× | 2nd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tauns Laboratories 197A.T | Japan | $327M | -3% | +7% | 29% | 16.7× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $327M | -24% | -10% | 4% | n/a | 15.8% | -4.5% |
| Jiangsu Apon Medical Technology 300753.SZ | China | $326M | -34% | -15% | -10% | 862.0× | 20.0% | -5.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $326M | -27% | +12% | -2% | n/a | n/a | n/a |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $336M | -36% | -5% | 2% | n/a | 34.3% | +0.4% |
| BioNote 377740.KS | South Korea | $337M | -14% | +12% | 18% | 14.4× | -15.0% | -28.5% |
| Japan Eyewear 5889.T | Japan | $318M | -5% | +15% | 32% | 10.7× | -9.4% | +20.2% |
| Nanjing Medlander Medical Technology 688273.SS | China | $337M | -47% | -12% | 8% | 17.5× | 35.3% | +5.2% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 25.2× | -0.3% | -0.7% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | n/a | n/a | n/a |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| Chongqing Xishan Science and Technology 688576.SS | China | $301M | -40% | -23% | -29% | 12.8× | n/a | n/a |
| Sanara MedTech SMTI | United States | $301M | +42% | +10% | 11% | 59.0× | 19.5% | +45.9% |
| Peijia Medical 9996.HK | Hong Kong | $296M | -34% | +21% | -13% | 292.4× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $291M | -46% | +8% | 24% | n/a | 3.1% | +16.4% |